European Journal of Neurology

Papers
(The H4-Index of European Journal of Neurology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
182
Issue Information116
Structural correlations between brain magnetic resonance image‐derived phenotypes and retinal neuroanatomy107
Central nervous system crystal‐storing histiocytosis: A case report and literature review101
Lessons from the past to understand the future99
CCR5‐Δ32polymorphism—a possible protective factor from gait impairment amongst post‐stroke patients97
Clusters of Comorbidities in Multiple Sclerosis and Their Influence on Healthcare Resource Usage88
Out‐of‐hospital versus in‐hospital status epilepticus: The role of etiology and comorbidities88
Advancements in targeted therapies for generalized acetylcholine receptor antibody positive myasthenia gravis: Beginnings of a paradigm shift84
Concerns Regarding “Small Fiber Morphology and Function in Inclusion Body Myositis—A Multimodal Assessment Including Confocal Corneal Microscopy”73
Cost‐effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health‐related quality of life72
Long‐Term Improvements Following Initial Migraine Response in Eptinezumab‐Treated Participants With Migraine for Whom 2–4 Prior Preventive Treatments Have Failed70
67
Response to erenumab assessed by Headache Impact Test‐6 is modulated by genetic factors and arterial hypertension: An explorative cohort study65
Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study65
Clinical and Genetic Reassessment in Patients With Clinically Diagnosed Hereditary Polyneuropathy63
57
Altered grey matter integrity and network vulnerability relate to epilepsy occurrence in patients with multiple sclerosis55
Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report55
ePoster55
Electroencephalography functional connectivity—A biomarker for painful polyneuropathy55
Comparative features and outcomes of major neurological complications of COVID‐1954
The effect of influenza vaccination on the rate of dementia amongst older adults54
Hearing impairment and development of parkinsonism and possible rapid eye movement sleep behaviour disorder: A CLSA prospective population‐based study54
Markers of Giant Cell Arteritis in Patients Presenting With Ischemic Stroke: A Scoping Review52
Neuropathy in GAA‐FGF14 Late‐Onset Cerebellar Ataxia (SCA27B): Prevalence and Characteristics50
Prevalence and Impact of Probable REM Sleep Behavior Disorder in Essential Tremor: A Multicenter Cross‐Sectional Study47
Correlation between patient‐reported manual ability and three objective measures of upper limb function in people with multiple sclerosis47
1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China47
Switching from ligand to receptor anti‐calcitonin gene‐related peptide (CGRP) antibodies or vice versa in non‐responders: A controlled cohort study46
The microbiome–gut–brain axis in epilepsy: pharmacotherapeutic target from bench evidence for potential bedside applications46
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment45
Basal ganglia ischaemic infarction after thrombectomy: cognitive impairment at acute stage45
Ischaemic cerebral small vessel disease caused by adenosine deaminase 2 deficiency syndrome44
A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis44
Contribution of Polygenic Scores to Progression Independent of Relapse Activity in Multiple Sclerosis43
Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms42
Prioritization process for European Academy of Neurology clinical practice guidelines41
Mindfulness or meditation therapy for Parkinson's disease: A systematic review and meta‐analysis of randomized controlled trials41
COQ2 and SNCA polymorphisms interact with environmental factors to modulate the risk of multiple system atrophy and subtype disposition41
Neurovascular Involvement in Fibromuscular Dysplasia: A Clue for Reappraisal of Old Classifications41
Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients41
0.17316889762878